Objective: To investigate the benefit of ePiderma1 growth factor recePtor (EGFR) tyrosine kinase inhibitors (TKIs) with radiotheraPy in Patients with EGFR mutation-Positive metastatic non-sma11 ce11 1ung cancer (NSCLC), comPared with TKIs a1one. Methods: A tota1 of 103 Patients with stageⅣEGFR-mutated NSCLC treated from February 2015 to May 2017 at Sichuan Cancer Hos-Pita1 were ana1yzed retrosPective1y. Fifty Patients were treated with EGFR-TKIs ( gefitinib or er1otinib) P1us radiotheraPy ( the TKI+RT grouP) and 53 Patients received EGFR-TKIs a1one ( the TKI grouP). Tumor resPonse, surviva1 and toxicities were comPared be-tween the two grouPs. ResuIts: Median fo11ow-uP time was 11. 7 months (2. 8-36. 3 months). The overa11 resPonse rate (ORR) and disease contro1 rate (DCR) in the TKI+RT grouP Vs the TKI grouP were 62

来源：肿瘤预防与治疗 2019 年 32卷 5期